Ovarian functions and polycystic ovary syndrome in adult women with type 1 diabetes mellitus in a Turkish population


Urhan E., Elbuken G., HACIOĞLU A., Karaca Z., Unluhizarci K., Kelestimur F.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2022
  • Doi Number: 10.1007/s40618-022-01946-9
  • Journal Name: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Keywords: Type 1 diabetes mellitus, Ovarian functions, Polycystic ovary syndrome (PCOS), Adult women, Turkish population, DIAGNOSTIC-CRITERIA, LUTEINIZING-HORMONE, YOUNG-WOMEN, PREVALENCE, GIRLS, HYPERANDROGENISM, MECHANISMS, MORPHOLOGY, PUBERTY, HEALTH
  • Erciyes University Affiliated: Yes

Abstract

Purpose The effect of gonadotropin-releasing hormone agonist (GnRHa) stimulation has not been studied in adult women with type 1 diabetes mellitus (DM). We investigated the baseline and stimulated hormone levels after GnRHa and the frequency and relationship between polycystic ovary syndrome (PCOS) and type 1 DM in adult women with type 1 DM. Methods We included 55 adult women (age, 17-35 years) with type 1 DM and 15 healthy women (age, 20-29 years). Hormones including total testosterone, androstenedione, dehydroepiandrosterone sulphate (DHEAS), follicle-stimulating hormone (FSH), luteinising hormone (LH), estradiol, prolactin, and thyroid-stimulating hormone were measured in the early follicular phase of the menstrual cycle. All participants underwent GnRHa stimulation test, and FSH, LH, estradiol and 17-OHP response levels were measured every 6 h for 24 h. PCOS was diagnosed according to ESHRE/ASRM (Rotterdam) criteria. Results Between patients with type 1 DM and healthy controls, no significant differences were noted in mean age and body mass index (BMI) as well as baseline and stimulated hormone levels after buserelin stimulation, except for baseline serum 17-OHP levels, which was higher in patients with type 1 DM. Polycystic ovary morphology (PCOM) was detected in 14 (25%) patients, clinical hyperandrogenism in 16 (29%), hyperandrogenemia in 25 (45%), anovulatory cycle in 72%, and PCOS in 20 (36%). Conclusion All parameters representing androgen excess disorders, except 17-OHP level, of both groups were similar, and frequencies of PCOS and anovulatory cycle in adult women with type 1 DM were 36% and 72%, respectively.